TRH (Thyrotropin) - Research Grade Peptide

TRH (Thyrotropin-Releasing Hormone) – Research-Grade Tripeptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade, sequence-defined protirelin tripeptide with batch documentation available where supplied
• Defined pyroglutamyl-histidyl-prolinamide molecular structure
• N-terminal pyroglutamate and C-terminal prolinamide incorporated into the specified molecular identity
• Supplied as measured dry or lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, molecular mass, peptide content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

TRH, also known as thyrotropin-releasing hormone, thyroliberin or protirelin, is a defined tripeptide comprising an N-terminal pyroglutamyl residue, L-histidine and C-terminal L-prolinamide. Each vial contains measured laboratory material prepared to support controlled scientific handling, storage, analytical method development and peptide characterisation. The stated nominal amount refers to the declared protirelin content of a single vial, subject to the applicable batch documentation and stated assay basis.

Where laboratory dissolution or reconstitution is required, the solvent, buffer, concentration, mixing procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. A universal solvent instruction should not be applied to every protirelin chemical form, salt presentation or formulation. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Catalogue Product Name: TRH (Thyrotropin-Releasing Hormone)
• Preferred Substance Name: Protirelin
• Alternative Names: TRH; thyrotropin-releasing hormone; thyrotropin-releasing factor; thyroliberin; synthetic TRH; Lopremone
• Terminology Clarification: Thyrotropin-releasing hormone should not be shortened to “thyrotropin” in the product title because thyrotropin ordinarily identifies the separate thyroid-stimulating hormone substance
• Material Classification: Synthetic sequence-defined pyroglutamyl tripeptide amide
• Sequence Length: Three amino-acid or modified amino-acid residues
• Complete Modified Sequence: pGlu-His-Pro-NH₂
• Expanded Sequence: L-pyroglutamyl-L-histidyl-L-prolinamide
• Alternative Structural Shorthand: Pyr-His-Pro-NH₂
• Sequence-Based Chemical Name: 5-oxo-L-prolyl-L-histidyl-L-prolinamide
• Systematic Chemical Name: (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
• N-Terminal Structure: L-pyroglutamate, also described as 5-oxo-L-proline
• C-Terminal Structure: C-terminal L-prolinamide
• Terminal-Modification Note: The N-terminal pyroglutamyl ring and C-terminal amide are integral parts of the defined protirelin molecular structure
• Cyclic or Linear Peptide: Linear tripeptide backbone containing a cyclic pyroglutamyl residue
• Cysteine Content: None
• Disulphide-Bond Content: None
• CAS Number: 24305-27-9
• PubChem Compound Identifier: CID 638678
• Unique Ingredient Identifier: 5Y5F15120W
• Molecular Formula: C₁₆H₂₂N₆O₄
• Average Molecular Weight: Approximately 362.38 g/mol
• Approximate Monoisotopic Mass: 362.1703 Da
• InChIKey: XNSAINXGIQZQOO-SRVKXCTJSA-N
• Formula Basis: The molecular formula and molecular weight describe the parent protirelin molecule containing its N-terminal pyroglutamate and C-terminal prolinamide, without an additional salt component, counter-ion, residual water, solvent or formulation excipient
• Physical Form: Dry powder or lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: Refer to the applicable batch Certificate of Analysis
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion should be stated in the batch Certificate of Analysis
• Purity Interpretation: Chromatographic purity represents the relative chromatographic composition measured under the stated analytical conditions and should not automatically be interpreted as equivalent to total net protirelin content
• Peptide-Content Specification: Net protirelin content should be distinguished from chromatographic purity and interpreted alongside water content, counter-ion content, residual solvents and formulation components
• Nominal Amount Basis: The applicable product specification should state whether the declared vial quantity is expressed as anhydrous parent protirelin equivalent or as total supplied salt-form or formulated lyophilised material
• Sequence Confirmation: The complete pGlu-His-Pro-NH₂ sequence should be confirmed using the applicable supplier, synthesis and batch records
• Stereochemical Confirmation: The specified L configuration of the pyroglutamyl, histidyl and prolinamide components should be supported by suitable synthesis records or analytical documentation
• N-Terminal Modification Confirmation: Molecular-identity documentation should confirm the pyroglutamyl residue and distinguish it from an uncyclised glutamine or glutamic-acid terminal form
• C-Terminal Amidation Confirmation: Molecular-identity documentation should confirm the C-terminal prolinamide and distinguish it from the corresponding free carboxylic acid derivative
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the specified protirelin structure
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied material is parent protirelin, a tartrate-containing form, an acetate-containing form or another salt or counter-ion presentation
• Counter-Ion Specification: Tartrate, acetate, trifluoroacetate or another counter-ion may affect the total supplied material mass, formula weight and calculated net protirelin content
• Water-Content Specification: Residual water and hydration state may contribute to the total material mass and should be stated or controlled through the applicable batch specification
• Residual-Solvent Specification: Applicable residual solvents arising from peptide synthesis, cleavage, purification, concentration and lyophilisation should be stated or controlled through the batch specification
• Related-Impurity Control: Uncyclised N-terminal material, C-terminal free-acid material, deletion products, truncated material, deamidated products and other synthesis-related or process-related substances are separate quality attributes
• Dissolution Method: The appropriate solvent, buffer, concentration and mixing procedure should be selected using the applicable batch documentation and validated laboratory method; a universal bacteriostatic-water instruction should not be applied to every protirelin chemical form or preparation
• Endotoxin Specification: The applicable bacterial endotoxin or lipopolysaccharide result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Sterility Distinction: A bacterial endotoxin or lipopolysaccharide result does not establish sterility. Sterility should only be claimed where supported by an appropriate validated sterility test and controlled filling process
• Analytical Interpretation: Molecular identity, modified sequence, stereochemistry, terminal structure, chromatographic purity, net peptide content, salt form, water content, residual solvents and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for the applicable batch.
✓ Certificate of Analysis – Accessible through the product QR code where a completed batch-specific document has been published.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The complete pGlu-His-Pro-NH₂ structure should be confirmed using the applicable synthesis and batch records.
✓ N-terminal modification documentation – The pyroglutamyl residue should be supported by appropriate molecular-identity data.
✓ C-terminal modification documentation – C-terminal prolinamide should be confirmed and distinguished from a free carboxylic acid structure.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified protirelin structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net protirelin content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ Chemical-form documentation – Parent protirelin, tartrate-containing, acetate-containing or another salt form should be identified clearly in the applicable product and batch records.
✓ Related-substance documentation – Terminally modified, deamidated, deletion-sequence and other process-related impurities should be controlled as applicable.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or lipopolysaccharide result should identify the analytical method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, terminal-modification, purification and analytical records are supplied.
✓ Trackable laboratory delivery – Securely packaged and dispatched using transport controls appropriate to the applicable batch stability and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

TRH and Protirelin Product Overview

Our TRH research-grade protirelin tripeptide is supplied for controlled analytical method development, peptide identity assessment, high-performance liquid chromatography evaluation, liquid chromatography–mass spectrometry workflows, impurity profiling, reference-material comparison and other scientific laboratory investigations.

Protirelin comprises the defined modified sequence pGlu-His-Pro-NH₂. The molecule contains an N-terminal L-pyroglutamyl residue, an L-histidyl residue and a C-terminal L-prolinamide. Both terminal structures form part of the molecular identity and should be confirmed together with the peptide sequence and molecular mass.

The CAS number 24305-27-9, molecular formula C₁₆H₂₂N₆O₄ and average molecular weight of approximately 362.38 g/mol describe the parent protirelin molecule. Where the supplied laboratory material contains tartrate, acetate, trifluoroacetate, residual water, solvents or formulation ingredients, the applicable batch documentation should identify their contribution to the total supplied material mass.

The product should be described as TRH, thyrotropin-releasing hormone, thyroliberin or protirelin. The shortened description “thyrotropin” is not appropriate because it refers to a different hormone substance and may create avoidable catalogue, analytical and documentation ambiguity.

Chromatographic purity should not automatically be interpreted as equivalent to total net protirelin content or proof of correct N-terminal pyroglutamate formation and C-terminal amidation. Molecular identity should be assessed using the applicable combination of chromatographic, mass-spectrometry, peptide-content and batch-manufacturing documentation.

A bacterial endotoxin or lipopolysaccharide result does not establish sterility, complete molecular identity, correct terminal modification or the absence of every peptide-related and process-related impurity. Any sterility claim must be supported separately by an appropriate validated sterility test and controlled production documentation.

For the majority of routine analytical method development, chromatographic assessment, mass-spectrometry comparison, impurity profiling and general laboratory work, the Regular TRH specification remains highly suitable. The premium black-and-gold ULTIMATE TRH option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin or lipopolysaccharide testing specification for projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet